Interleukin 5 and interleukin 2 cooperate with interleukin 4 to induce IgG1 secretion from anti-Ig-treated B cells by unknown
INTERLEUKIN 5 AND INTERLEUKIN 2 COOPERATE WITH
INTERLEUKIN 4 TO INDUCE IgG1 SECRETION FROM
ANTI-IgTREATED B CELLS
BY JEFFREY M . PURKERSON,' MICHAEL NEWBERG,' GWENDOLYN WISE,*
KEVIN R. LYNCH,'l AND PETER C . ISAKSON'
From the Departments of 'Pharmacology and :Biochemistry, The University of Virginia
Medical School, Charlottesville, Virginia 22908
Exposure of murine splenic B cells to insoluble anti-Ig for 48 h yields low density
B cell blasts (anti-Ig blasts) that proliferate and secrete IgM when recultured with
either LPS or T cell-derived lymphokines (1, 2). Culture of anti-Ig blasts with a
mixture of T cell-derived lymphokines that includes IL-4 (EL4 Sn) (1, 2) results
in secretion of IgGI, which is blocked by monoclonal anti-IL-4 (1). Thus, IL-4 can
alter Ig isotype expression in B cells pre-activated by anti-Ig. However, IL-4 alone
does not sustain proliferation nor promote differentiation of anti-Ig blasts (1, 2), sug-
gesting that other lymphokines are required to enable IL-4-induced IgGl secretion.
We have examined the effects of other T cell-derived lymphokines on IL-4-mediated
IgGI secretion. While IL-4 was capable of suppressing IgM secretion from LPS-
stimulated anti-Ig blasts, secretion of IgGI required lymphokines in addition to IL-
4, including IL-5 and IL-2.
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Mice.
￿
BALB/c mice were obtained from Cumberland Farms, Clinton, TN and used at
6-12 wk of age.
Reagents.
￿
Affinity-purified antibodies were obtained fromJackson Immunoresearch, Avon-
dale, PA (goatanti-mouse IgM + IgG, and anti-w chain and anti-y chain), and from Southern
Biotechnology Associates, Birmingham, AL (goat anti-IgGI, and goat anti-1c). Myeloma stan-
dards were obtained from Litton Bionetics, Charleston, SC (MOPC 21). Monoclonal rat
anti-IL-4 (11B11) was generously provided by Dr. E. S. Vitetta (Southwestern Medical School,
Dallas, TX). Radiochemicals were obtained from New England Nuclear, Boston, MA.
Salmonella typhosa LPS was purchased from Difco Laboratories Inc., Detroit, MI.
T Cell Supernatants.
￿
Lymphokine-containing supernatant (Sn) was obtained from EL4 cells
as previously described, except serum-free conditions were used (3). IL-4-depleted Sn, [(D)EL4
Sn] was prepared by twice passing EL4 Sn over an anti-IL-4 affinity column (11B11-Sepharose,
see below).
Lymphokines.
￿
rIL-2 was provided by Dr. J. Farrar (Hoffman-LaRoche, Inc., Nutley, NJ).
rIL-5 was produced in Xenopus oocytes, as described (4), using a plasmid containing IL-5
cDNA provided by Dr. T. Honjo (Kyoto University, Kyoto, Japan). 1 U of IL-5 was defined
as the amount of IL-5 required for 1/3 maximal stimulation of [3H]thymidine incorpora-
tion by BCLI cells. IL-4 was affinity purified from EL-4 Sn using a 11B11-Sepharose column
as described by Ohara et al. (5). 1 U of IL-4 was defined as the amount of IL-4 required
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for 1/3 maximal stimulation of [3H]thymidine incorporation by splenic B cells cultured with
anti-Ig-sepharose. 1-5 U/ml IL-4 stimulates maximal IgGl secretion from LPS-stimulated
B cells.
B CellPreparations.
￿
B cells were prepared by treating spleen cells with antiThy-1 and L3T4
followed by lysis with baby rabbit serum (Pel-Freeze Biologicals, Rogers, AR). In some ex-
periments splenic B cells were isolated by panning on anti-Ig-coated plates. High density B
cells (1.081-1.086 g/ml) were isolated on discontinuous Percoll density gradients as described (2).
Cell Culture.
￿
Anti-Ig blasts were prepared from high density or unfractioned splenic B
cells isolated by centrifugation (400g for 10 min) over Ficoll-Hypaque (Pharmacia Fine Chem-
icals, Piscataway, NJ) as described (1, 2). Blasts were washed and recultured (in RPMI 1640,
5% FCS, 5 gg/ml gentamicin, and 50 pM 2-ME) at 2 x 104 cells/0.2 ml with 20 pg/ml LPS
in 96-well microtiter plates. All additions were made in triplicate.
RIA.
￿
Culture supernatant was assayed for Ig isotypes by solid-phase RIA (1).
Results
Lymphokine Dependence ofIL-4-mediated IgG1 Secretionfrom Anti-IgBlasts.
￿
IL-4 stimu-
lates secretion of IgG1 from resting B cells in the presence of LPS (6-9), and from
anti-Ig blasts in concert with other lymphokines (1). We first asked whether LPS
and affinity-purified IL-4 were sufficient to elicit IgG1 secretion from anti-Ig blasts.
In contrast to results with resting B cells, culture of anti-Ig blasts with LPS and
IL-4 at concentrations up to 50 U/ml had virtually no effect on IgG1 secretion (Fig.
1). Addition of T cell-derived lymphokines from IL-4-depleted EL4 Sn [(D)EL4
Sn] stimulated IgG1 secretion from anti-Ig blasts treated with LPS + IL-4. IgG1
secretion in the presence of (D)EL4 Sn and LPS was half maximal at -5 U/ml IL-4,
and was inhibited by monoclonal anti-IL-4. Secretion of IgGl from anti-Ig blasts
cultured with IL-4 + (D)EL4 peaked at 6 d of culture, whereas LPS + IL-4 failed
to enhance IgG1 secretion when secondary cultures were extended to 8 d (not shown).
In the absence of IL-4, (D)EL4 Sn enhanced background IgG1 secretion an average
of twofold in five experiments. Cell recoveries at the end of 5-d cultures were also
increased 50-100% by (D)EL4 Sn (data not shown).
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FIGURE 1.
￿
IL-4-mediated enhancement of
IgG1 secretion is dependent on other T cell-
derived lymphokines. Anti-Ig blasts were pre-
pared from high density B cells as described
in Materials and Methods, then recultured
at 105/ml with LPS (20 gg/ml) or LPS +
(D)EL4 Sn (5 pl) for 6 d. 111111 (monoclonal
anti-IL-4) = 1 pg/ml. Results presented are
the mean of triplicate wells from a represen-
tative experiment.PURKERSON ET AL.
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FIGURE 2.
￿
rIL-5 and rIL-2 stimulate IL-4-dependent IgG1 secretion from anti-Ig blasts. Anti-Ig
blasts prepared from high density B cells (A) or from cells that adhered to anti-Ig-coated plates
(B) were recultured with LPS (20 gg/ml) + lymphokines for 5 (A) or 7 d (B). (A) rIL-2 = 20
U/ml; rIL-5 = 10 U/ml. (B) IL-4 = 5 U/ml; IL-2 = 50 U/ml.
next wished to identify the lymphokine(s) in EL4 Sn that allowed IgG1 secretion
from anti-Ig blasts. Two lymphokines present in EL-4 Sn that have demonstrated
activity on Bcells are IL-5 and IL-2. Since IL-2, IL-4, andIL-5, alone or in combi-
nation (Simpson, L. G., J. M. Purkerson, and P C. Isakson, manuscript in prepara-
tion), stimulate scant proliferation or Ig secretion from anti-Ig blasts, it was neces-
sary to include LPS as a mitogen in these experiments. Thus, anti-Ig blasts were
cultured with LPS and IL-4, in combinations with rIL-5 and rIL-2. Neither rIL-2
or rIL-5 enhanced background IgG1 secretion in the presence of LPS (<100 ng/ml).
In contrast, when combined with 5 U/ml IL-4, rIL-5 stimulated IgG1 secretion up
to 10-fold (Fig. 2, A and B); half maximal responses occurred at N3 U/ml of rIL-5.
Stimulationof IgG1 secretionby rIL-2 plus IL-4 was variable, rangingfrom no effect
to a 2-3-fold increase in IgG1. However, addition of rIL-2 consistently increased
the IgG1 response to rIL-5 + IL-4 by 2-3-fold. The IgG1 response to the combina-
tion of rIL-2, IL-4, and rIL-5 ranged from 40 to 100% of that obtained with crude
EL-4 Sn (not shown). Cell recoveries from 5-d secondary cultures were increased
<50o 7o by rIL-5 + rIL-2.
IL-4 Suppresses IgMSecretionfrom Anti-IgBlasts.
￿
The preceding experiments sug-
gest that anti-Ig blasts may be unresponsive to IL-4 in the absence of other lym-
phokines. Since IL-4 has been shown to markedly suppress IgM secretion from LPS-
stimulated B cells (8), we askedwhether IL-4 could exert this effect on anti-Igblasts.
IgM secretion from LPS-treated anti-Igblasts was strikingly inhibited by IL-4 (Fig.
3, A and B) over the same concentration range that stimulated IgG1 secretion in
the presence of other lymphokines (compare with Figs. 1 and 2); IgM suppression
was reversed by anti-IL-4. Cells cultured with (D)EL-4 Sn and LPS produced two-
fold more IgM than cellscultured with LPS alone; in the presence of both LPS and
(D)EL4 Sn, IL-4 suppressed IgM secretion by >80% (Fig. 3 B).BRIEF DEFINITIVE REPORT
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￿
IL-4 suppresses IgM secretion from
anti-Ig blasts. Anti-Ig blasts prepared from high
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Discussion
The present findings indicate that B cellspre-activated by anti-Igdiffer from resting
B cells with respect to lymphokine requirements for isotype switching to IgGl. Al-
though IL-4 (in thepresence of LPS) stimulates IgG1 secretion from resting B cells
(6-9), additional T cell-derived lymphokines were required to obtain IgG1 secre-
tion from anti-Igblasts. In addition suppression ofIgM secretionby IL-4 was clearly
dissociated from its enhancement of IgG1 secretion on anti-Ig blasts.
Several explanations appear plausible for the differences in lymphokine require-
ments for IgG1 secretion observed between B cells and anti-Igblasts. Pretreatment
with anti-Ig may prevent some of the actions of IL-4, so that the requirement for
IL-5 may be unique to anti-Ig pretreated B cells. Alternatively, LPS and anti-Ig
may stimulate distinct B cell subsets that have different lymphokine requirements
for Ig isotype regulation. The subset of B cellsthat secretes IgG1 in response to LPS
+ IL-4 may have received prior stimulation in vivo (perhaps from T cells), thus
allowing isotype regulation by IL-4 in the absence of other lymphokines. We have
noted that anti-Ig blasts cultured with LPS secrete lower quantities ofall IgG iso-
types (but not IgM) than do LPS-treatedsplenic Bcells, consistent with the hypoth-
esis that distinct B cell subsets are stimulated by LPS vs. anti-Ig.
1178 PURKERSON ET AL.
40 DIL-4 + 111311 A
O IL-4
35
30PURKERSON ET AL.
￿
BRIEF DEFINITIVE REPORT
￿
1179
The mechanism(s) by which IL-5 (and IL-2) facilitates IL-4-mediated IgG1 secretion
is not clear. The observation that IL-4 alone suppresses IgM secretion (Fig. 3) demon-
strates that anti-Ig blasts are capable of responding to IL-4 in the absence of other
lymphokines. Thus, IL-5 may promote proliferation and/or Ig secretion from cells
precommitted to IgG1 production, as has been shown with IgA secretion from LPS-
stimulated Peyer's patch B cells (10). However, IL-5 alone had little effect on either
background IgGl secretion or cell recovery from cultures of anti-Ig blasts, suggesting
that IL-5 does more than promote differentiation of precommitted cells. The data
presented in Figs. 2 and 3 are consistent with the hypothesis that IL-5 and IL-4
both regulate molecular aspects of isotype switching. Since IL-4 alone is capable
of suppressing IgM secretion, it is interesting to speculate that IL-4 may initiate
recombinational events that lead to decreased expression of CHg, while IL-5 may
regulate events that complete IL-4-directed switch recombination to CHY1 .
Summary
We have analyzed requirements for IL-4-induced secretion ofIgGl from anti-Ig-
activated B cells. Activated B cell blasts prepared by culture of high density B cells
with anti-Ig failed to secrete IgG1 upon subsequent culture with LPS and IL-4. How-
ever, IL-4 markedly suppressed IgM secretion in the same cultures. Addition of a
mixture of T cell-derived lymphokines or rIL-5 to LPS-stimulated anti-Ig blasts
restored IL-4-stimulated IgGI secretion; rIL-2 further enhanced the response to IL-
4 + HL-5 . These results suggest that IL-4, IL-5, and IL-2 cooperate in the regula-
tion of B lymphocyte Ig isotype expression .
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